Generic Name and Formulations:
Nebivolol (as HCl) 2.5mg, 5mg, 10mg, 20mg; tabs.
Indications for BYSTOLIC:
≥18yrs: initially 5mg once daily. Individualize; may increase at 2-week intervals; max 40mg/day. Severe renal or moderate hepatic impairment: initially 2.5mg once daily.
<18yrs: not recommended.
Severe hepatic impairment (Child-Pugh >B). Severe bradycardia. 2nd- or 3rd-degree AV block. Cardiogenic shock. Overt heart failure. Sick sinus syndrome (unless paced).
CHF. Angina. Recent MI. Bronchospastic disease. Diabetes. Hyperthyroidism. Severe renal impairment. Moderate hepatic impairment. Avoid abrupt cessation (taper over 1–2 weeks). Surgery. Peripheral vascular disease. Pheochromocytoma. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with phenylalkylamine and benzothiazepine calcium channel blockers (eg, verapamil, diltiazem), antiarrhythmics (eg, disopyramide), digoxin, reserpine, guanethidine; monitor. May be potentiated by CYP2D6 inhibitors (eg, quinidine, propafenone, paroxetine, fluoxetine); may need to reduce dose. If on both nebivolol and clonidine, discontinue nebivolol before tapering clonidine. May block epinephrine.
Headache, fatigue, dizziness, GI upset.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Light Therapy May Prevent Depression During Hospitalization Post-Transplant in Multiple Myeloma
- Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible
- TNFi Not Linked to Increased Risk for Cancer Recurrence in Rheumatoid Arthritis
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer